|
|
S. Eddahibi, N. Hanoun, L. Lanfumey, K.P. Lesch, B. Raffestin, M. Hamon, S. Adnot
J Clin Invest. 2000;
105(11):1555
doi:10.1172/JCI8678
Abstract |
Full text
| PDF

H
ypoxia is a well-recognized stimulus for pulmonary blood vessel remodeling and pulmonary hypertension development. One mechanism that may account for these effects is the direct action of hypoxia on the expression of specific genes involved in vascular smooth muscle cell (SMC) proliferation. Previous studies demonstrated that the serotonin (5-hydroxytryptamine; 5-HT) transporter (5-HTT) mediates the mitogenic activity of 5-HT in pulmonary vascular SMCs and is overexpressed during hypoxia. Thus, 5-HT-related mitogenic activity is increased during hypoxia. Here, we report that mice deficient for 5-HTT (5-HTT–/–) developed less hypoxic pulmonary hypertension and vascular remodeling than paired 5-HTT+/+ controls. When maintained under normoxia, 5-HTT–/–-mutant mice had normal hemodynamic parameters, low blood 5-HT levels, deficient platelet 5-HT uptake, and unchanged blood levels of 5-hydroxyindoleacetic acid, a metabolite of 5-HT. After exposure to 10% O2 for 2 or 5 weeks, the number and medial wall thickness of muscular pulmonary vessels were reduced in hypoxic 5-HTT–/– mice as compared with wild-type paired controls. Concomitantly, right ventricular systolic pressure was lower and right ventricle hypertrophy less marked in the mutant mice. This occurred despite potentiation of acute hypoxic pulmonary vasoconstriction in the 5-HTT–/– mice. These data further support a key role of 5-HTT in hypoxia-induced pulmonary vascular SMC proliferation and pulmonary hypertension.
Citation information
This citation data is accumulated from CrossRef, which receives citation information from participating publishers, including this journal.
Not all publishers participate in CrossRef, so this information is not comprehensive.
Additionally, data may not reflect the most current citations to this article,
and the data may differ from citation information available from other sources
(for example, Google Scholar, Web of Science, and Scopus).
About CrossRef
| Title and authors |
Publication |
Year |
. |
Amelioration of hypoxia-induced striatal 5-HT2A receptor, 5-HT transporter and HIF1 alterations by glucose, oxygen and epinephrine in neonatal rats
T.R. Anju, C.S. Paulose |
NEUROSC LETT |
2011 |
.
|
Tamara Tajsic, Nicholas W. Morrell |
Comprehensive Physiology |
2010 |
.
|
Pulmonary Circulation
Sheila G. Haworth, Marlene Rabinovitch |
Paediatric Cardiology |
2010 |
.
|
The serotonin transporter, gender, and 17 oestradiol in the development of pulmonary arterial hypertension
K. White, Y. Dempsie, M. Nilsen, A. F. Wright, L. Loughlin, M. R. MacLean |
cardiovas res |
2010 |
.
|
New therapies for pulmonary arterial hypertension: an update on current bench to bedside translation
Laurence Dewachter, Céline Dewachter, Robert Naeije |
Expert Opin Invest Drugs |
2010 |
.
|
Pulmonary hypertension: therapeutic targets within the serotonin system
Y Dempsie, M R MacLean |
British Journal of Pharmacology |
2009 |
.
|
The angiopietin-1-Tie2 pathway prevents rather than promotes pulmonary arterial hypertension in transgenic mice
L. Kugathasan, J. B. Ray, Y. Deng, E. Rezaei, D. J. Dumont, D. J. Stewart |
j exp med |
2009 |
.
|
Novel interactions between the 5-HT transporter, 5-HT1B receptors and Rho kinase in vivo and in pulmonary fibroblasts
K M Mair, M R MacLean, I Morecroft, Y Dempsie, T M Palmer |
British Journal of Pharmacology |
2009 |
.
|
FLUOXETINE PROTECTS AGAINST MONOCROTALINE-INDUCED PULMONARY ARTERIAL HYPERTENSION: POTENTIAL ROLES OF INDUCTION OF APOPTOSIS AND UPREGULATION OF Kv1.5 CHANNELS IN RATS
Feng-Guo Zhai, Xin-Hua Zhang, Huai-Liang Wang |
Clin Exp Physiol Pharmacol |
2009 |
.
|
Synergistic heterozygosity for TGF??1 SNPs and BMPR2 mutations modulates the age at diagnosis and penetrance of familial pulmonary arterial hypertension
John A. Phillips, Justin S. Poling, Charles A. Phillips, Krista C. Stanton, Eric D. Austin, Joy D. Cogan, Lisa Wheeler, Chang Yu, John H. Newman, Harry C. Dietz, James E. Loyd |
Genet Med |
2008 |
.
|
Serotonin (5-HT) Transporter Ligands Affect Plasma 5-HT in Rats
Richard B. Rothman, Dorota Zolkowska, Michael H. Baumann |
New York Academy of Science |
2008 |
.
|
The role of gene polymorphisms in the pathogenesis of chronic obstructive pulmonary disease
Eva Slabá, Pavol Joppa, Ján Šalagovič, Ružena Tkáčová |
Biologia |
2008 |
.
|
Molecular pathogenesis of pulmonary arterial hypertension
Marlene Rabinovitch |
Journal Clinical Investigation |
2008 |
.
|
Role of the serotonin transporter in pulmonary arterial hypertension
Yvonne Dempsie, Margaret R MacLean |
Expert Rev Clin Pharmacol |
2008 |
.
|
Medical therapy for pulmonary arterial hypertension
James A Driscoll, Murali M Chakinala |
Expert Opinion Pharmacotherapy |
2008 |
.
|
Targeting the murine serotonin transporter: insights into human neurobiology
Dennis L. Murphy, Klaus-Peter Lesch |
Nat Rev Neurosci |
2008 |
.
|
Interactions between integrin αIIbβ3 and the serotonin transporter regulate serotonin transport and platelet aggregation in mice and humans
Ana Marin D. Carneiro, Edwin H. Cook, Dennis L. Murphy, Randy D. Blakely |
Journal Clinical Investigation |
2008 |
.
|
Serotonin: a review
L. F. MOHAMMAD-ZADEH, L. MOSES, S. M. GWALTNEY-BRANT |
J Vet Pharmacol Ther |
2008 |
.
|
New insights on receptor-dependent and monoamine oxidase-dependent effects of serotonin in the heart
J. Mialet-Perez, P. Bianchi, O. Kunduzova, A. Parini |
J Neural Transm |
2007 |
.
|
Vasoactive peptides in cardiovascular (patho)physiology
Glaucia Callera, Rita Tostes, Carmine Savoia, M N Muscara, Rhian M Touyz |
Expert Rev Cardiovasc Ther |
2007 |
.
|
|
|
|